Quick Answer
Actinium Pharmaceuticals, Inc. reported Research And Development Expense of $21.12 million for the year ending 2025.
- Actinium Pharmaceuticals, Inc. showed a decrease of -29.7% in Research And Development Expense from 2024 to 2025.
- This data is from Actinium Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Actinium Pharmaceuticals, Inc.'s Research And Development Expense has grown by 6,424.0%.
- Historical annual values: Fiscal year 2025: $21.12 million | Fiscal year 2024: $30.05 million | Fiscal year 2023: $38.67 million | Fiscal year 2022: $23.14 million | Fiscal year 2021: $18.03 million | Fiscal year 2020: $16.09 million | Fiscal year 2019: $16.55 million | Fiscal year 2018: $17.09 million | Fiscal year 2017: $17.72 million | Fiscal year 2016: $17.83 million | Fiscal year 2015: $13.50 million | Fiscal year 2014: $12.27 million | Fiscal year 2013: $3.11 million | Fiscal year 2012: $3.44 million | Fiscal year 2011: $323.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: